Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme

Abstract Introduction Biosimilars have provided additional treatment options for patients with immune-mediated inflammatory diseases. This study evaluated the real-world use of adalimumab biosimilar ABP 501 in European patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic a...

Full description

Bibliographic Details

Published in:	Rheumatology and Therapy
Main Authors:	Ran Jin, James M. Haughton, Emily J. Goddard, Delphine Courmier, Waldemar Radziszewski, Rachael H. Meadows, James Piercy, Stanley Cohen
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2025-03-01
Subjects:	Adalimumab Ankylosing spondylitis Biosimilar Patient-reported outcomes Psoriasis Psoriatic arthritis
Online Access:	https://doi.org/10.1007/s40744-025-00755-9